Logo

Gilead Unveils the Price of Remdesivir as $390 per Vial in Developed Countries

Share this

Gilead Unveils the Price of Remdesivir as $390 per Vial in Developed Countries

Shots:

  • Gilead will price its COVID-19 treatment at $390/ vial in the US and other developed countries- with a 5days treatment course of 6 vials costing $2340/ patient while the price for private insurance companies will be $520/ vial
  • Pricing the remdesivir at low value ensures the broad and equitable access for the therapy during the pandemic. The company has signed an agreement with HHS where HHS and states will decide on hospital allocations of the therapy until the end of Sept’2020. After that- HHS will not handle the allocation
  • In developing countries- Gilead collaborated with multiple generic makers to deliver remdesivir at low cost

Click here to read full press release/ article | Ref: Gilead  | Image: Gilead

Related News: Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions